Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Desarrollo de Fármacos

Hyemin Lee¹, Elizabeth L Zoeller¹, Gregory A Cary²

¹Emory University, Atlanta, GA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association

|December 25, 2025

Resumen

Los investigadores identificaron interacciones proteicas clave que involucran a TICAM1 (molécula adaptadora que contiene el dominio TIR 1) para dirigirse a la respuesta inmune innata en la enfermedad de Alzheimer (EA). Se desarrollaron ensayos para cribar inhibidores de moléculas pequeñas, ofreciendo un enfoque terapéutico novedoso para la EA.

Área de la Ciencia:

Neurociencia
Inmunología
Farmacología

Sus antecedentes:

TICAM1 (molécula adaptadora que contiene el dominio TIR 1) está implicada en el riesgo de enfermedad de Alzheimer (EA) y la respuesta inmune innata.
TICAM1 vincula los receptores tipo Toll con la respuesta al interferón tipo 1, un factor clave en la patogénesis de la EA.
TICAM1 está regulado al alza en cerebros con EA y presenta múltiples objetivos para el desarrollo de fármacos.

Objetivo del estudio:

Validar las interacciones proteína-proteína (IPP) de TICAM1.
Desarrollar estrategias de cribado para dirigirse a la vía de TICAM1 en la EA.
Identificar posibles inhibidores de moléculas pequeñas para la intervención terapéutica.

Principales métodos:

Metanálisis de estudios existentes de alto y bajo rendimiento sobre las IPP de TICAM1.
Validación experimental de los interactores de TICAM1 identificados utilizando ensayos NanoPCA y TR-FRET.
Desarrollo de ensayos de cribado para monitorizar las interacciones de TICAM1.

Principales resultados:

Se confirmaron varias interacciones proteína-proteína (IPP) de TICAM1 reportadas utilizando ensayos NanoPCA y TR-FRET.
Se identificaron las IPP de TICAM1 con TBK1, TRAF3 y DHX36 como objetivos clave de intervención.
Se establecieron ensayos de cribado para inhibidores de moléculas pequeñas dirigidos a la vía de TICAM1.

Conclusiones:

La focalización de las IPP de TICAM1 ofrece una estrategia novedosa para modular la respuesta inmune innata en la EA.
Se identificaron IPP clave y ensayos de cribado para el desarrollo temprano de fármacos.
Esta investigación contribuye a los esfuerzos del Centro TREAT-AD en la terapéutica de la enfermedad de Alzheimer.

Palabras clave:

Enfermedad de Alzheimer TICAM1 Inhibidores de moléculas pequeñas Respuesta inmune innata Desarrollo de fármacos

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Videos de Conceptos Relacionados

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...